Ellipsis Biotherapeutics Corporation announced today that it now offers SNP genotyping using both Illumina and Beckman Coulter technologies.
Toronto, (PRWEB) May 28, 2005 -- Ellipsis Biotherapeutics Corporation
announced today that it now offers SNP genotyping using both the Illumina
GoldenGate(TM) and Beckman Coulter SNPstream(TM) technologies.
"The addition of the Illumina system to our existing SNPstream platform allows us the unique opportunity to accomodate all SNP genotyping projects, ranging in size from quite small to very large", commented Laurence Rubin, CEO of Ellipsis. "We are very excited to offer this complete suite of SNP genotyping solutions to our clients".
Ellipsis Biotherapeutics Corporation was founded in 1997 to commercialize the disease gene discovery efforts of its founders, primarily in the area of inflammatory disease. Since then, it has leveraged its expertise in SNP genotyping to provide high quality service to a variety of clients in academic, government and industrial research settings. For more information, see the company’s website at www.ellipsisbio.com or call the Manager, Genotyping Services at (416) 586-0947.
# # #
Source : http://www.prweb.com/releases/2005/5/prweb245171.htm